Recent findings on phosphoinositide-3 kinase in rheumatic diseases

Japanese Journal of Clinical Immunology

Volumn 35, Issue 1, 2012, Pages 8-13

  Tamura, Naoto ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Phosphoinositide 3 kinase (PI3K); PI3K inhibitor; rheumatic disease; therapy

Indexed keywords

EID: 84979874001     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.35.8     Document Type: Article

References (22)

1. Cantley L. C. : The phosphoinositide 3-kinase pathway. Science ; 296 : 1655, 2002.
2. Okkenhaug K., Bilancio A.,Farjot G.,et al. : Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science ; 297 : 1031, 2002.
3. Ramadani F.,Bolland D. J.,Garcon F.,et al. : The PI3K isoform p110alpha and P110delta are essential for pre3B cell receptor signaling and B cell development. Sci Signal ; 3 : Ra50, 2010.
4. Suzuki H.,Terauchi Y.,Fujiwara M.,et al. : Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science ; 283 : 390–392, 1999.
5. Baracho G. V.,Miletic A. V., Omori S. A., et al. : Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol ; 23 : 1783, 2011.
6. Harada Y.,Harada Y.,Elly C.,et al. : Transcription factors Foxo3a and Foxo1 couple the E3 li-gase Cbl-b to the induction of Foxp3 expression in inducd regulatory T cells. J Exp Med ; 207 : 1381–1391, 2010.
7. Delgoffe G. M., Kole T. P., Zheng Y.,et al. : The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity ; 30 : 832–844, 2009.
8. Lee K.,Gudapati P.,Dragovic S.,et al. : Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity ; 32 : 743–753, 2010.
9. Arbuckle M. R., McClain M. T., Rubertone M. V., et al. : Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med ; 349 : 1526–1533, 2003.
10. Flores-Borja F.,Kabouridis P. S., Jury E. C., et al. : Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum ; 52 : 3955–3966, 2005.
11. Borlado L. R., Redondo C.,Alvarez B.,et al. : Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J ; 14 : 895–903, 2000.
12. Barber D. F., Bartolome A.,Hernandez C.,et al. : PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med ; 11 : 933–935, 2005.
13. Taher T. E., Parikh K.,Flores-Boria F.,et al. : Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes form patients with sysytemic lupus erythematosus. Arthritis Rheum ; 62 : 2412–2423, 2010.
14. Suarez-Fueyo A.,Barber D. F., Martines-Ara J.,et al. : Enhanced phosphoinositide 3-kinase γ activity is a frequent event in systemic lupus erythematosus that confers resistance to activatio-induced T cell death. J Immunol ; 187 : 2376–2385, 2011.
15. Zhang H.,Wang Y.,Xie J.,et al. : Regulation of tumor necrosis factor alpha-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis Rheum 44 : 1555–1567, 2001.
16. PAP T.,Franz J. K., Hummel K. M., et al. : Activation of synovial fibroblasts in rheumatoid arthritis: Lack of expression of the murine tumor suppressor PTEN at sites of invasive growth and destruction. 2 : 59–64, 2002.
17. Kim K. W., Cho M. L., Park M. K., et al. : Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB3 dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 7: 139, 2005.
18. Yaguchi S.,Izumisawa Y.,Sato M.,et al. : In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives. Biol Pharm Bull 20 : 698, 1997.
19. Yaguchi S.,Fukui Y.,Koshimizu I.,et al. : Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 98 : 545, 2006.
20. Toyama S.,Tamura N.,Haruta K.,et al. : Inhibitory effects of ZSTK474, a novel phosphoinositide-3 kinase on osteoclasts and collagen-induced arthritis in mice. Arthritis Res Ther 12 : R92, 2010.
21. Yamane K.,Ihn H.,Tamaki K. : Epidermal growth factor upregulates expression of transforming growth factor beta receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway : Resistance to epidermal growth factor stimulation in scleroderma fibroblasts. Arthritis Rheum 48 : 1652–1666, 2003.
22. Mori S.,Kamachi F.,Sasaki A.,et al. : ZSTK474, a phosphatidylinositol 3-kinase inhibitor, ameliorates ankylosing enthesitis in DBA/1 mice. Arthritis Rheum 60 (Suppl 10) : 1442, 2009.